Indonesian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
thyroid neoplasms/tyrosine
Tautan disimpan ke clipboard
Halaman 1 dari 33 hasil
Cancer and Blood Pressure Management, CARISMA Study
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
PRIMARY OBJECTIVE:
I. To determine the feasibility of an intensive (systolic blood pressure [SBP] < 120 mmHg) "Intervention" versus standard care (SBP < 140 mmHg) "Non-Intervention" approach to blood pressure (BP) control in metastatic renal cell and thyroid cancer patients initiating
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Even though the prognosis of advanced GIST has been tremendously improved by the introduction of tyrosine kinase inhibitors, the vast majority of patients will develop secondary resistance to these agents.
The therapeutic options of patients with advanced GIST with resistance (or intolerance) to
Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
This study is design to prospectively investigate the safety and efficacy of apatinib in downsizing primary tumors and metastatic lesions in patients with metastatic and advanced differentiated thyroid cancers before RAI Treatment.
Standard treatment of thyroid cancer includes thyroidectomy, RAI
Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Soft tissue sarcoma (STS) is a relatively rare type of malignant tumor. For patients with recurrent/distant metastasis/unresectable advanced soft tissue sarcoma, chemotherapy with doxorubicin and ifosfamide is the standard treatment, but the effect is limited.
Targeted drugs represented by
Rehabilitation Program in Patients With Acromegaly
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Acromegaly is a rare, chronic, disabling disease of endocrine origin that causes several debilitating systemic dysfunctions due to the excessive production of growth hormone (GH) and insulin-like growth factor I (IGF-I) (Gadelha et al., 2017).
In 98% of cases, the disease is caused by a sporadic
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Population: Patients with advanced progressive 131I-refractory DTC or MTC will be enrolled to this study. Forty-five patients responding to TKI therapy (defined as 50% drop in tumor marker level within the first two months of treatment) will be randomized to receive TKI therapy either through
Cabozantinib in Advanced Salivary Gland Cancer Patients
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Rationale: Salivary gland cancer (SGC) is a rare cancer with 24 histological subtypes. Treatment options for locally advanced and/or metastatic SGC are limited. The tyrosine kinase inhibitor cabozantinib suppresses tumor growth, angiogenesis, and metastasis, and has been approved for renal cell
Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
This phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess efficacy and safety in patients with 131I-refractory/resistant differentiated thyroid cancer.The study is a randomised,multicentre,double-blind,placebo-controlled,study.
Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
See brief summary
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Bladder cancer is the 9th most common cancer worldwide, with around 429.800 new cases diagnosed in 2012 and the 5th most common cancer in Europe, with more than 151.000 new cases diagnosed in 2012. Relating mortality figures, bladder cancer is the 13th most common cause of cancer death worldwide,
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
This is a Phase I/II research study, which means that researchers are testing different doses of the drug alectinib in participants with cancer to evaluate its safety, determine a safe dosage range, and identify side effects.
The FDA (the U.S. Food and Drug Administration) has approved alectinib as
Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Primary Outcome Measure: Progression free survival of apatinib in RAIR-DTC.
Secondary Outcome Measures: Disease control rate, objective response rate, duration of response, changes of Tg and TgAb level in serum, overall survival, side effects and quality of life.
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
This phase 2 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess efficacy and safety in patients with 131I-refractory/resistant differentiated thyroid cancer.The study is a randomised,multicentre,open-label study.
Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Carcinomas of the salivary glands (SGCs) are rare, (less than 1% of all cancers of the head and neck and include more than 20 malignant histotypes. They can occur both in major and minor salivary glands, are locally aggressive, demonstrating invasiveness that leads to involvement of the facial
Database tanaman obat terlengkap yang didukung oleh sains
- Bekerja dalam 55 bahasa
- Pengobatan herbal didukung oleh sains
- Pengenalan herbal melalui gambar
- Peta GPS interaktif - beri tag herba di lokasi (segera hadir)
- Baca publikasi ilmiah yang terkait dengan pencarian Anda
- Cari tanaman obat berdasarkan efeknya
- Atur minat Anda dan ikuti perkembangan berita, uji klinis, dan paten
Ketikkan gejala atau penyakit dan baca tentang jamu yang mungkin membantu, ketik jamu dan lihat penyakit dan gejala yang digunakan untuk melawannya.
* Semua informasi didasarkan pada penelitian ilmiah yang dipublikasikan
